Anthem Bioscienc Q2 FY27 Earnings Call — Analysis (NSE: ANTHEM)
Anthem Biosciences reported Q2 FY27 revenue of ₹594 Cr with an industry-leading 50.6% EBITDA margin and reaffirmed its ₹1,200 Cr Unit 4 Phase 1 capex plan targeting March 2028 commissioning.
Result quality: strong — Margin expansion. Management sentiment: optimistic.
The take
H1FY27 H1 Consolidated Revenue ₹1,012 Cr ( -7% YoY ) . Guidance raised — FY27 fy27 specialty ingredients reve… 20% . New story: Order-book-driven recovery .
Results
Q2 FY27 consolidated revenue stood at ₹594 Cr with EBITDA of ₹330 Cr (50.6% margin) and PAT of ₹211 Cr (32.04% margin); H1 FY27 revenue reached ₹1,012 Cr with 46.2% EBITDA margin.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated Revenue from Operations | ₹594 Cr | none · Q2FY27 · CRDMO ₹509 Cr, Specialty Ingredients ₹85 Cr | |
| EBITDA | ₹330 Cr | none · Q2FY27 · Includes other income of ₹59 Cr | |
| EBITDA Margin | 50.6% | none · Q2FY27 · Includes other income | |
| Profit Before Tax (PBT) | ₹296 Cr | none · Q2FY27 | |
| Profit After Tax (PAT) | ₹211 Cr | none · Q2FY27 · PAT margin 32.04% | |
| H1 Consolidated Revenue | ₹1,012 Cr | -7% | yoy · H1FY27 · CRDMO ₹850 Cr, Specialty Ingredients ₹162 Cr |
| H1 EBITDA | ₹506 Cr | none · H1FY27 · Margin 46.2%; includes ₹84 Cr other income | |
| H1 PAT | ₹331 Cr | none · H1FY27 · PAT margin 30.2% | |
| Net Cash Position | ₹1,534 Cr | point_in_time · Q2FY27 · As of September 30, 2026 |
Guidance
Reiterated ₹1,200 Cr capex guidance for Unit 4 Phase 1 across 30 acres with commissioning targeted around March 2028, and expect FY26 margin levels to be sustainable full year.
What management committed to
- Specialty Ingredients will constitute at least 20% of full-year FY27 revenue. — 20%, FY27
- At least a few of the nine late-phase projects will commercialize in FY27. — FY27
Key themes
Commercial ramp-up and Unit 4 capex expansion
How the narrative shifted
- Quarterly lumpiness is structural: Q1 weakness was followed by a strong Q2 rebound, with management explicitly projecting sequential catch-up through Q3 and Q4, underscoring the structural lumpiness tied to customer delivery schedules.
- Order-book-driven recovery: Q2's strong catch-up validates the recovery thesis and provides concrete evidence of the order book materializing.
- Capacity investment for visible pipeline: The narrative expanded from Unit 4 capacity to include specific modality investments (biologics, oligos, ADCs, peptides) in response to customer pipeline visibility.
- Innovation defends industry-leading margins: Q2's margin performance (50.6%) dramatically validated the innovation thesis, though Gawir Baig carefully walked back the specific 50% number as a full-year guidance, anchoring on the FY26 baseline as the sustainable floor.
- Big Pharma M&A creates long-term opportunity: The narrative moved from a general opportunity to specific claims of retained exclusivity and wallet share expansion post-acquisition.
- GLP-1 as pending regulatory catalyst: The specific Semaglutide approval catalyst was not mentioned, shifting the narrative focus to the broader peptide pipeline without a near-term regulatory hook.
- Cost discipline and ESOP tailwind: Ongoing cost efficiencies, yield optimization, and workforce productivity are cited as supporting factors for the margin improvement, though ESOP costs were not specifically highlighted this call.
- Biotech funding revival drives RFP inflow: Management acknowledged a noticeable increase in queries and RFPs over the last quarter driven by revived biotech funding, though the environment was characterized as a 'mixed bag' due to geopolitical uncertainty.
- New modalities investment (Biologics, Oligos, ADC, Peptides): bullish
Operational commentary
- Commercial portfolio expanded to 15 commercial molecules (1 added in Q2 FY27 from an emerging biotech chronic care program) and 9 late-stage Phase 3 molecules.
- China procurement reliance reduced to 20-21% of procurement (down over the last 18 months), with domestic procurement reaching 75-78% via captive vendor development.
- Exports contribute 84% of revenue (Europe ~60%, US 22-24%), while domestic sales contribute 16%.
- Commercial manufacturing contributes 65% of the CDMO segment revenue, with early R&D and development supplies contributing the remaining ~20% equally.
- Customer concentration remains high with top 5 customers contributing ~50% and top 10 contributing ~80% of revenue.
- Unit 4 Phase 1 is a 30-acre facility equivalent in capacity to Units 1, 2, and 3 combined, with 30-35% allocation towards biology/fermentation.
- Currently the sole supplier for all 5 newly commercialized molecules over the last 18 months, with underlying aggregate market potential estimated in excess of $10B.
Analyst Q&A
Q. Details, therapeutic indication, and peak sales estimates for the newly commercialized molecule in Q2 FY27.
Declined to share molecule-specific details, indications, or peak sales due to customer confidentiality, confirming only that it belongs to chronic care from an emerging biotech portfolio.
Q. Expected contribution and revenue percentage from new technologies (peptides, ADCs, oligonucleotides) by FY31.
Declined to quantify FY31 revenue share from new modalities, citing dependency on clinical progression timelines, but noted over a decade of capability building.
Q. How many of the 9 late-stage Phase 3 molecules are expected to commercialize over the next 18-24 months.
Explained that commercialization depends strictly on clinical trial readouts which are outside Anthem's control, though a few could potentially cross over within this financial year.
Research and educational content only. Not investment advice.